CVS Health Corp.

The FTC settlement resolves all litigation and investigations tied to CVS's PBM and pharmacy businesses, removing a major regulatory overhang. Truist and Wells Fargo responded by raising their price targets to $118 and $123 respectively, signaling that long-term Street conviction in CVS remains intact despite short-term headwinds.

The structural changes forced on Caremark — abandoning rebate guarantees, eliminating spread pricing, and aligning member cost sharing with net drug costs — are prompting investors to reassess the unit's future earnings power. Combined with a $440 million Omnicare legal cash outflow, the consent order materially alters a core revenue engine.

CVS raised its full-year 2026 adjusted EPS guidance to $7.30–$7.50, driven by stronger medical cost controls at Aetna and improved Caremark profitability. Analysts project further EPS growth of 12.5% year-over-year in fiscal 2027, and the company has beaten Wall Street's bottom-line estimates in each of its past four quarterly reports.

TIKR's valuation model shows that with the stock near $99–$107, the mid-case scenario implies only a ~6% annualized return through 2030. Most analyst optimism has already been priced in through successive upward revisions, with the Street's consensus target sitting only modestly above current price levels.

Financhill's 52-week price forecast of $119.70 implies a 12.4% upside from current levels, consistent with CVS's long-run historical average annual gain. With a Stock Score of 72/100 — well above its historic median of 50 — and the stock trading above its 5, 20, and 50-day moving averages, the technical and historical setup supports further appreciation.

Wall Street Zen downgraded CVS from buy to hold, citing a valuation that already trades at a premium to peers. The stock is near its 52-week high, and the consensus average price target of roughly $104–$112 offers limited spread over the current share price, suggesting the near-term risk/reward has deteriorated.